Silencing human genetic diseases with oligonucleotide-based therapies. (Q38089634)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

title

Silencing human genetic diseases with oligonucleotide-based therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Tamara Martínez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Natalia Wright

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Ana Isabel Jiménez

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Covadonga Pañeda

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

language of work or name

1 reference

14 March 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

page(s)

481-493

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23494242%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00439-013-1288-1

26 February 2020

exact match

0 references

cites work

RNAi therapeutics: principles, prospects and challenges

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Diagnosis and therapeutic approaches to transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The next generation of hemophilia treatment specialists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Pharmacological strategies for lowering LDL cholesterol: statins and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Microsatellite repeat instability and neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA-based therapeutics: current progress and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Liquid movement across the surface epithelium of large airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Human cholesterol metabolism and therapeutic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The CFTR and ENaC debate: how important is ENaC in CF lung disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Progress in antisense technology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Current prospects for RNA interference-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Genetics and molecular pathogenesis of the myotonic dystrophies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Apolipoprotein polymorphisms and familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Determinants of specific RNA interference-mediated silencing of human beta-globin alleles differing by a single nucleotide polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA interference is mediated by 21- and 22-nucleotide RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Therapeutic approaches to muscular dystrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Mipomersen sodium: a new option for the treatment of familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Progress and challenges in RNA interference therapy for Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

SiRNA-mediated selective inhibition of mutant keratin mRNAs responsible for the skin disorder pachyonychia congenita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Huntington's disease: from pathology and genetics to potential therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Challenges in developing therapies for rare diseases including pachyonychia congenita

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

In vivo application of an RNAi strategy for the selective suppression of a mutant allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA interference technologies and therapeutics: from basic research to products

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Nucleic acid delivery: the missing pieces of the puzzle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNA interference in the clinic: challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The current clinical management of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Progress toward in vivo use of siRNAs-II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Antisense-based therapy for the treatment of spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Biologically inspired synthetic enzymes made from DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Ribozyme- and deoxyribozyme-strategies for medical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The activation and physiological functions of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Modification of globin gene expression by RNA targeting strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Familial hypercholesterolemia: present and future management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The genetic basis of pachyonychia congenita.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Splicing fidelity, enhancers, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery dis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

A review of α1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Therapeutics development for spinal muscular atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Targeted mRNA degradation by double-stranded RNA in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Apolipoprotein B synthesis inhibition: results from clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Antisense oligonucleotides for the treatment of dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

21 January 2018

Antisense therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00439-013-1288-1

HD Therapeutics - CHDI Fifth Annual Conference.

21 January 2018

1 reference

12 December 2020

The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion

1 reference

12 December 2020

Adult cystic fibrosis

1 reference

12 December 2020

Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia

1 reference

12 December 2020

Potential therapeutic applications of decoy oligonucleotides.

1 reference

12 December 2020

Antisense therapeutics: a promise waiting to be fulfilled

1 reference

12 December 2020

Local dystrophin restoration with antisense oligonucleotide PRO051

1 reference

12 December 2020

Fomivirsen for the treatment of cytomegalovirus retinitis

1 reference

12 December 2020

Gene therapy for Duchenne muscular dystrophy

1 reference

12 December 2020

RNAi therapeutics: the teenage years

1 reference

12 December 2020